MedTrace Logo

MINERVA: MINimizE Right Ventricular Pacing to Prevent Atrial Fibrillation and Heart Failure

NCT00262119 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1300

Last updated 2025-07-02

Study results available
· View outcomes & findings →

Summary

The aim of this study is to test the impact of the managed ventricular pacing (MVP) mode and atrial preventive and antitachycardia pacing therapies on the reduction of a composite clinical outcome composed of any death, permanent atrial fibrillation, and cardiovascular hospitalizations.

Conditions

Interventions

DEVICE

Pacemaker Medtronic EnRhythm

Pacemaker specific programming

Sponsors & Collaborators

  • Medtronic Cardiac Rhythm and Heart Failure

    lead INDUSTRY

Principal Investigators

  • Luigi Padeletti, Prof. · Ospedale Careggi - Firenze

  • Giuseppe Boriani, Dr. · Ospedale Sant'Orsola - Bologna

  • Luis Mont, Dr. · Hospital Clinic of Barcelona

  • Reinhard C Funck, Dr. · Philipps University Hospital - Marburg

  • Carsten W Israel, Dr. · J. W. Goethe University Hospital - Frankfurt

  • Helmut Pürerfellner, Dr. · Elisabethinen Hospital

  • Antonis S Manolis, Prof. · Evagelismos Hospital - Athens

  • André Pisapia, Dr · Hôpital Saint-Joseph - Marseille

  • Raymond Tukkie, Dr · Kennemer Gasthuis

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2012-04-30
Completion
2013-04-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00262119 on ClinicalTrials.gov